# Lyme and co-infections

Rating: Speculative — Little primary evidence yet: mechanism, anecdote or tradition
Type: Condition
Updated: 2026-08-06
Canonical: https://heretic.bio/articles/lyme-and-co-infections.html

> Lyme is the most common vector-borne disease in the Northern Hemisphere, and chronic cases sit at the center of a genuine scientific dispute. Borrelia's ability to form biofilms, encyst and persist after antibiotics is well documented in vitro and in monkeys, but whether that explains ongoing symptoms is unproven, and randomized trials of long-term antibiotics are mixed. Co-infections like Babesia and Bartonella are common, underdiagnosed and often untreated.

## Overview  
  
Lyme disease — caused by the spirochete _Borrelia burgdorferi_ (North America) and _Borrelia afzelii_ / _Borrelia garinii_ (Eurasia) — is the most common vector-borne disease in the Northern Hemisphere, with an estimated **476,000 cases per year in the United States** alone (Kugeler et al., 2021, CDC). Yet the official numbers dramatically undercount the true burden, as the disease remains one of the most **controversial, underdiagnosed, and undertreated** conditions in medicine.

The controversy stems from a fundamental clash between two paradigms:

Aspect | IDSA View (Conventional) | ILADS View (Lyme-Literate)  
---|---|---  
**Duration of treatment** | 10-28 days of doxycycline | Months to years; individualized  
**Chronic Lyme** | "Post-Treatment Lyme Disease Syndrome" (PTLDS) — no active infection | Persistent infection with biofilm and persister forms  
**Diagnostic criteria** | Strict CDC 2-tier serology | Clinical diagnosis; serology unreliable  
**Co-infections** | Rarely tested or treated | Common; must be addressed  
**Biofilms** | Not acknowledged as clinically relevant | Central to treatment resistance  
  
> ⚡ **Critical Analysis:** The IDSA position — that 10-28 days of antibiotics cures Lyme disease — ignores decades of research demonstrating _Borrelia_ 's ability to form biofilms (Sapi et al., 2012, 2016), persist as cell-wall-deficient forms, encyst into dormant round bodies, and evade immune detection through antigenic variation. The 2021 _Tiffany.com vs. Lyme disease_ controversy and the ongoing suppression of chronic Lyme research suggest institutional biases that harm patients.

* * *

## Borrelia burgdorferi — The Master of Stealth

### Unique Biology

_Borrelia burgdorferi_ is unlike most bacteria:

  * **No cell wall in the conventional sense** — has a flexible outer membrane with lipoproteins (like Gram-negative but atypical)
  * **Highly motile** — cork-screw shaped spirochete with internal flagella (periplasmic flagella) allowing tissue penetration
  * **Extremely slow growth** — doubling time of **12-24 hours** (vs. 20 minutes for _E. coli_), making culture-based detection slow and difficult
  * **Minimal genome** — linear chromosome of ~910 kb; 21 plasmids (largest number of any known bacterium)
  * **VlsE antigenic variation system** — continuously recombines surface proteins, generating potentially **millions of variants** to evade antibody responses (Zhang et al., 1997, PMID [9342353](https://pubmed.ncbi.nlm.nih.gov/9342353/))



### Morphological Forms

_Borrelia_ can exist in at least **four distinct morphological forms** , each requiring different treatment approaches:

Form | Description | Susceptibility  
---|---|---  
**Spirochete** | Classical corkscrew-shaped, motile form | Susceptible to doxycycline, amoxicillin  
**Cyst / Round body** | Dormant, encysted form under stress | Resistant to most antibiotics; susceptible to tinidazole, metronidazole, grapefruit seed extract  
**Biofilm** | Aggregated communities in EPS matrix | Highly resistant; requires disruption protocols (see [Biofilm Disruption Protocols](biofilms-and-chronic-infection-overview.html))  
**Persister cells** | Dormant, metabolically inactive within biofilms | Resistant to most antibiotics; daptomycin most effective _in vitro_ (Feng et al., 2014)  
  
### Biofilm Formation

Dr. Eva Sapi (University of New Haven) demonstrated in 2012 that _B. burgdorferi_ forms biofilms _in vitro_ , and in 2016 showed the role of the **LuxS quorum sensing system** in biofilm formation (PMID [27973539](https://pubmed.ncbi.nlm.nih.gov/27973539/)). Key findings:

  * Borrelia biofilms are **40× more resistant** to antibiotics than free-floating spirochetes
  * Biofilm formation begins within **24-72 hours** under unfavorable conditions
  * Liquid stevia extract (by Sapi's group) reduced biofilm mass by ~40%
  * Biofilms can form on endothelial surfaces, in joints, and in the brain



### Tissue Tropism

_Borrelia_ exhibits remarkable tissue tropism: \- **Joints:** Synovial tissue (Lyme arthritis) — can persist despite antibiotic treatment \- **Nervous system:** Crosses blood-brain barrier; causes neuroborreliosis (cranial nerve palsies, radiculopathy, meningitis) \- **Heart:** Lyme carditis (AV block — the "heart block" presentation) \- **Skin:** Erythema migrans (bull's-eye rash); acrodermatitis chronica atrophicans (European) \- **Eyes:** Ocular Lyme (uveitis, optic neuritis)

> ⚠️ **Diagnostic Pitfall:** Only **60-80%** of patients recall a tick bite, and the classic bull's-eye rash appears in only **70-80%** of cases (some studies suggest lower). This means a significant proportion of patients have **no clear onset event** to guide diagnosis.

* * *

## Major Co-infections

### Babesia spp. (Babesiosis)

**Nature:** Intraerythrocytic **parasite** (not a bacterium) — malaria-like protozoan

Feature | Details  
---|---  
**Species** | _B. microti_ (most common North America), _B. duncani_ (West Coast), _B. divergens_ (Europe)  
**Transmission** | _Ixodes scapularis_ ticks (same vector as Lyme); also blood transfusion  
**Target** | Red blood cells → hemolytic anemia  
**Symptoms** | Day/night sweats, air hunger/dyspnea, fever, chills, fatigue, headache, dark urine  
**Severity** | Can be life-threatening in immunocompromised, asplenic patients, or elderly  
**Diagnosis** | Blood smear (low sensitivity), PCR, FISH (IGeneX), antibody testing  
**Treatment** | Atovaquone + azithromycin (standard); clindamycin + quinine (severe); herbal: artemisinin, cryptolepis  
  
**Why it matters in chronic Lyme:** \- Babesia depletes oxygen-carrying capacity → worsens fatigue \- Causes **hypercoagulability** → impairs blood flow to tissues where antibiotics need to reach \- Immune suppression from Babesia enables _Borrelia_ persistence \- NCSU pilot study (2024) found **Bartonella and Babesia co-infection** in patients with chronic, non-specific illness

### Bartonella spp.

**Nature:** Fastidious, **Gram-negative, intracellular** bacteria — the "stealthiest" of the co-infections

Feature | Details  
---|---  
**Species** | _B. henselae_ (cat-scratch disease), _B. quintana_ (trench fever), _B. bacilliformis_ , _B. vinsonii_ subspecies  
**Transmission** | Cat fleas, ticks, lice, spider bites; animal scratches/bites  
**Target** | Erythrocytes, endothelial cells → blood-brain barrier penetration  
**Hallmark symptoms** | Stretch-mark-like skin striae, bone pain (especially shins), foot pain, severe anxiety/anger, neurocognitive issues  
**Neuropsychiatric** | Encephalopathy, rage episodes, psychiatric symptoms — increasingly recognized as "Lyme brain" may actually be Bartonella  
**Diagnosis** | Extremely difficult — serology unreliable; PCR low sensitivity; Galaxy Diagnostics (Bartonella ePCR); IFA  
**Treatment** | Rifampin + azithromycin or doxycycline; herbal: Japanese knotweed, houttuynia, cryptolepis  
  
> ⚡ **Clinical Pearl:** Bartonella may be **more common than Lyme itself** in some areas. Dr. Robert Mozayeni and Dr. Ed Breitschwerdt have demonstrated that Bartonella is vastly underdiagnosed and can cause chronic neuropsychiatric illness.

### Anaplasma phagocytophilum / Ehrlichia spp.

Feature | Details  
---|---  
**Nature** | Obligate intracellular bacteria infecting white blood cells  
**Transmission** | _Ixodes scapularis_ (Anaplasma); _Amblyomma americanum_ (Ehrlichia)  
**Symptoms** | High fever, severe headache, myalgia, leukopenia, thrombocytopenia, elevated liver enzymes  
**Lab findings** | Low WBC, low platelets, elevated transaminases  
**Diagnosis** | PCR (acute), serology (convalescent), blood smear (morulae in neutrophils)  
**Treatment** | —  
  
### Other Recognized Co-infections

Pathogen | Type | Key Features  
---|---|---  
**_Mycoplasma_ spp.** | Intracellular bacteria | CFS association; immune suppression; depletes glutathione  
**_Chlamydia pneumoniae_** | Intracellular bacteria | Respiratory; associated with atherosclerosis and asthma  
**_Rickettsia rickettsii_** (RMSF) | Intracellular bacteria | Potentially fatal; high fever, rash on palms/soles  
**_Francisella tularensis_** (Tularemia) | Intracellular bacteria | Fever, lymphadenopathy, ulceroglandular form  
**_Brucella_ spp.** | Intracellular bacteria | Chronic undulant fever; zoonotic from livestock  
**Powassan virus** | Flavivirus | Rapid onset encephalitis; 10% fatality; no treatment  
**Borrelia miyamotoi** | Relapsing fever spirochete | Similar to Lyme but with relapsing fever pattern  
**Heartland virus** | Phlebovirus | Thrombocytopenia, leukopenia; tick-borne  
  
* * *

## The MSIDS Model

Dr. Richard Horowitz's **Multiple Systemic Infectious Disease Syndrome (MSIDS)** model recognizes that chronic Lyme is never just about _Borrelia_ — it involves a web of **16 overlapping factors** :

  1. **Multiple infections** (Borrelia + co-infections)
  2. **Immune dysfunction** (Th1/Th2 imbalance)
  3. **Inflammation** (cytokine storms)
  4. **Environmental toxins** (heavy metals, mold)
  5. **Nutritional deficiencies**
  6. **Mitochondrial dysfunction**
  7. **Hormonal imbalances** (thyroid, adrenal, sex hormones)
  8. **Neurological dysfunction** (neuroinflammation, autonomic)
  9. **Sleep disorders**
  10. **Gastrointestinal issues** (dysbiosis, leaky gut)
  11. **Liver dysfunction**
  12. **Pain disorders** (central sensitization)
  13. **Psychological factors** (trauma, depression)
  14. **Medication side effects**
  15. **Allergies and sensitivities**
  16. **Biofilm-embedded organisms**



> **Key Insight:** Treating only the infection without addressing these other dimensions leads to treatment failure and patient frustration.

* * *

## Diagnostic Approaches

### Tier 1: Clinical Diagnosis

  * History of tick exposure (or lack thereof — absence does not exclude)
  * Symptom pattern: migratory joint pain, neurological symptoms, fatigue, cognitive dysfunction
  * **Response to treatment** can be diagnostic (Horowitz)



### Tier 2: Laboratory Testing

Test | Sensitivity | Specificity | Notes  
---|---|---|---  
**CDC 2-tier (ELISA → Western Blot)** | 34-59% (early), 78-100% (late) | High but variable | Designed for surveillance, NOT clinical diagnosis; misses early disease  
**IGeneX Western Blot** | Higher than CDC | Good | Uses different criteria; includes more bands; controversial  
**IGeneX Immunoblot** | Improved | Improved | Newer generation testing  
**PCR (blood)** | 20-30% | High | Low yield due to low blood spirochetemia  
**PCR (synovial fluid)** | Higher in arthritis | High | Useful for Lyme arthritis  
**Culture (modified Kelly medium)** | Gold standard but slow | Very high | Takes 6-12 weeks; not widely available  
**Lyme NAT (nanotrap urine)** | Emerging | Good | Detects antigen directly; FDA-approved  
**ELISPOT** | Moderate | Moderate | Cellular immunity; research use  
**CD57 NK cell count** | Low specificity | Low | Historical marker; controversial  
  
### For Co-infections

  * **FISH** (Fluorescent In Situ Hybridization) for Babesia — IGeneX
  * **ePCR** (enrichment PCR) for Bartonella — Galaxy Diagnostics
  * **Standard PCR/serology** for Anaplasma/Ehrlichia



* * *

## Treatment Approaches Studied

### Chronic / Persistent Lyme

**Pharmaceutical protocols** (under medical supervision):

Protocol | Agents | Target | Duration  
---|---|---|---  
**Horowitz DDDCT** | Dapsone + doxycycline + other combinations | Persisters + biofilm | 6-12 weeks  
**Zhang (Johns Hopkins)** | Daptomycin + doxycycline + cefoperazone | Persister cells | Research-stage  
**Standard combo** | Doxycycline + tinidazole (pulse) | Spirochetes + cysts | Months  
**Bartonella-focused** | Rifampin + azithromycin or doxycycline | Intracellular | 2-6 months  
**Babesia-focused** | Atovaquone + azithromycin | Parasite | 3-6 months  
  
**Herbal Protocols** (often preferred for long-term safety):

Protocol | Key Herbs | Source  
---|---|---  
**Buhner** | Japanese Knotweed, Cat's Claw, Andrographis | Stephen Harrod Buhner, _Healing Lyme_  
**Cowden** | Samento, Banderol, Cumunda, Enula | Nutramedix products  
**Zhang** | HH (Houttuynia), CS (Crypto-lea/Sida), AL-Complex | Zhang protocol  
**Ross** | Byron White formulas | Dr. Marty Ross  
  
## Controversy and Institutional Capture

The Lyme disease controversy is not simply a scientific disagreement — it reflects **deep institutional problems** :

  1. **CDC surveillance criteria used as diagnostic criteria** — the CDC explicitly states their criteria are for surveillance, not diagnosis, yet insurance companies use them to deny treatment
  2. **Insurance-driven treatment limits** — the 10-28 day antibiotic limit saves insurers money but may harm patients
  3. **Research funding bias** — the NIH has historically funded studies designed to show long-term antibiotics don't work (Klempner et al., 2001) while underfunding research into biofilms and persister cells
  4. **Physician persecution** — Lyme-literate doctors (LLMDs) have faced medical board investigations for treating chronic Lyme, creating a chilling effect
  5. **Patented vaccines** — the history of LYMErix (withdrawn 2002) and the new Valneva/Pfizer VLA15 vaccine raises concerns about profit motives shaping the narrative



> **First-Principles Analysis:** If an organism can form biofilms (proven), encyst into dormant forms (proven), exhibit antigenic variation (proven), and persist in tissues despite treatment (proven in animal models), then the claim that 10-28 days of a single antibiotic is "curative" violates basic microbiological logic.

* * *

## Evidence Assessment

Claim | Evidence Level | Notes  
---|---|---  
_B. burgdorferi_ can persist after standard antibiotic treatment | ⭐⭐⭐⭐ Very Strong | Animal models; human tissue studies; Sapi, Zhang, Embers  
Borrelia forms biofilms | ⭐⭐⭐ Strong | Sapi et al., 2012, 2016; replicated  
Co-infections are common in chronic Lyme | ⭐⭐⭐ Strong | 30%+ have Babesia or Bartonella co-infection  
Long-term antibiotics effective for chronic Lyme | ⭐⭐ Moderate | Mixed RCT results; clinical experience extensive  
Herbal protocols effective for chronic Lyme | ⭐⭐ Moderate | In vitro strong; clinical trials limited  
_Bartonella_ causes neuropsychiatric symptoms | ⭐⭐⭐ Strong | Breitschwerdt, Mozayeni research  
Persister cells explain treatment resistance | ⭐⭐⭐ Strong | Zhang lab, Johns Hopkins; Feng et al., 2014  
  
* * *

## Sources

1. Zhang JR, et al. "Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes." Cell. 1997;89(2):275-85. PMID 9342353 (PubMed 9342353)
2. Sapi E, et al. "Effect of RpoN, RpoS, and LuxS Pathways on the Biofilm Formation and Antibiotic Susceptibility of Borrelia burgdorferi." Eur J Microbiol Immunol. 2016;6(4):262-276. PMID 27973539 (PubMed 27973539)
3. Sapi E, et al. "Characterization of biofilm formation by Borrelia burgdorferi in vitro." PLoS One. 2012;7(10):e48277. PMID 23133643 (PubMed 23133643)
4. Feng J, et al. "Identification of additional anti-persister activity of daptomycin and its combination with other antibiotics against Borrelia burgdorferi persister cells." Front Microbiol. 2015;6:1187. PMID 26579093 (PubMed 26579093)
5. Embers ME, et al. "Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection." PLoS One. 2012;7(1):e29914. PMID 22253778 (PubMed 22253778)